Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Ten patients with prostatic carcinoma--six with stage C and four with stage D disease--were treated for 6 weeks to 12 months with agonistic analogues of luteinizing hormone-releasing hormone (LH-RH). [D-Trp6]LH-RH was given subcutaneously once daily at a dose of 100 microgram and [D-Ser(But)6]des-Gl...

Cijeli opis

Bibliografski detalji

Izdano u:	Proc Natl Acad Sci U S A
Glavni autori:	Tolis, G, Ackman, D, Stellos, A, Mehta, A, Labrie, F, Fazekas, A T, Comaru-Schally, A M, Schally, A V
Format:	Artigo
Jezik:	Inglês
Izdano:	National Academy of Sciences 1982
Teme:	Research Article
Online pristup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC346035/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6461861/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.79.5.1658
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!